about
Antiphospholipid syndrome in pediatrics.Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaborationPreliminary criteria for global flares in childhood-onset systemic lupus erythematosusRelative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritisMulti-antibody composition in lupus nephritis: isotype and antigen specificity make the difference.Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.Patterns of clinical remission in select categories of juvenile idiopathic arthritis.Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study.Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus.Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?Consensus procedures and their role in pediatric rheumatology.The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisDamage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.Developing outcome measures for paediatric rheumatic diseases.An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Advances and challenges in imaging in juvenile idiopathic arthritis.Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus ErythematoTowards a role of ultrasound in children with juvenile idiopathic arthritis.Glucocorticoids in juvenile idiopathic arthritis.Advances in biomarkers for paediatric rheumatic diseases.Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.Clinical features and correct diagnosis of macrophage activation syndrome.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation CollA Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis.Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation CollMutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry.Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.Wegener granulomatosis in a child: cutaneous findings as the presenting signs.Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
P50
Q33377008-3A562AD0-29B6-49C6-9A4F-EC2B4C3A70C8Q33386883-BC8DFE99-BB94-4636-B5D9-63A988E204ABQ33962448-9DEFEAFB-141A-4FA8-B354-ED2DD90335A1Q34109962-04889B81-F9F7-4D0D-A839-256DB171A910Q34196828-20B8253B-3FE9-4634-BEA6-7ACA33195BEBQ34632661-040A01EC-CD54-4581-B01F-0F491FF4435EQ35102471-45463E8D-6ACE-492F-8C24-9113EFEAE0EFQ35199345-7F97A222-9D9D-46D1-86B9-8269A3DBD8C4Q35555214-B7C2BD2F-521D-43D8-AAA9-76137E35996FQ35608355-C25AC923-8443-4789-822E-B04E3F866F43Q35755515-693A1A5E-01EE-43ED-BEB0-FA585AE17D3BQ36178472-3F23BB07-FF34-43C2-A8D6-3B9B51FCF1E8Q36299612-F3BE1DB3-E13A-45B1-861E-0FD834293F15Q36346681-1E67CEF2-4DFD-4C8A-9E93-3A48D42F8E9EQ36552356-41B24D89-A2DF-4A89-8351-07FCD2326117Q36581673-4BE92EED-5F91-4E74-8EE7-9D9AE5E5EEEFQ36915642-6CF1F616-FC46-4B0B-99AF-6D04D8890658Q37155925-A69965CA-E9B0-4A75-812D-D2B83EA4CC99Q37293030-068893F2-A394-49E5-B1D9-42FCFC852206Q37475947-BD30324A-D31E-4132-8C3E-CA24C1AEF268Q37620825-02A76B5F-73AB-4EBC-AEB0-E4830CAF4201Q37834144-926F9ED6-39A3-4AF4-9EF9-D51A4318201BQ37993678-772A3DA4-766B-47F2-8D79-0E6203B5729FQ37997306-B3F536BE-8BC7-4E31-AF5B-967FAA83CFF1Q38010353-4E64BE7C-4262-467D-8B6A-B41E3EBEE7A0Q38059101-88B7C837-3292-45C0-AC27-19C6F450970AQ38250159-FA749E98-0A0D-43E2-B309-052B84F23988Q38289816-11B35598-DA6C-4F73-AFC9-94B0052A6453Q38374642-57DEBA24-065E-4B4C-84D1-EF1F4408C47EQ38530013-EDC7F4F0-8A0D-4919-876C-2EBCBE5766C2Q38575277-2728F111-0E0D-4B8D-A03D-00398717BFDBQ38691413-5B2A8B7D-1FAA-41E4-AE89-AFD17F9DD1DFQ38697343-F75180BB-0B91-4E8F-BA91-CC8786C5C62CQ38729149-1AF81822-12FE-487D-B34E-11D0E49816CAQ39761819-C0F4063E-F527-446F-AABA-568B8EC26A36Q40032766-48F963E0-6540-4738-A0BA-CA25040AD6EFQ40064593-FD9F344C-BAEA-40B3-91DA-E865CD3C9545Q40198507-D7BACE5B-9D2F-4CA0-9D55-104570A33FF1Q40633608-9D5AAEA1-505D-41C9-BC89-E6FF40EE0547Q41068374-A37D8BCA-09BC-47E9-827E-31C1629AC117
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Ravelli
@ast
Angelo Ravelli
@en
Angelo Ravelli
@es
Angelo Ravelli
@nl
type
label
Angelo Ravelli
@ast
Angelo Ravelli
@en
Angelo Ravelli
@es
Angelo Ravelli
@nl
prefLabel
Angelo Ravelli
@ast
Angelo Ravelli
@en
Angelo Ravelli
@es
Angelo Ravelli
@nl
P106
P1153
7006272421
P21
P214
260144782958682690678
P31
P496
0000-0001-9658-0385
P5008
P735
P7859
viaf-260144782958682690678